Zurex Pharma develops a novel antimicrobial technology platform focused on preventing health care-associated infections, with an initial product candidate, ZurexPrep™, for pre-surgical skin preparation. The company completed a pivotal Phase 3 program for ZurexPrep™, reporting favorable efficacy versus the market-leading product. Zurex is preparing its first New Drug Application (NDA) submission to the U.S. Food and Drug Administration and is in the final stages of formally submitting the NDA. The recent capital raise will support the NDA submission and FDA review and fund ongoing platform development activities. Management emphasizes that regulatory approval of ZurexPrep™ would validate the platform and enable a broader portfolio of infection-prevention and wound-care products. The company is based in Middleton, Wis. Zurex Pharma develops a proprietary antimicrobial technology platform and product candidates aimed at preventing healthcare-associated infections. Its lead product, ZuraPrep™, is intended to help prevent surgical site infections. The company plans to use recently raised funds to support pivotal Phase III clinical trials of its lead compound. Zurex targets infections occurring in inpatient, ambulatory and home care settings, and has a stated focus on surgical site wounds and catheter-related infections. The company’s mission is to develop and commercialize a portfolio of innovative antimicrobial products. Zurex announced an initial Series C close exceeding $6 million to support these clinical and corporate objectives. Zurex Pharma is a Middleton, Wisc.-based life sciences company that develops and commercializes a portfolio of innovative antimicrobial products. Its product focus is preventing healthcare-acquired infections, particularly surgical site wounds and catheter-related infections. The company is led by President and CEO Carmine Durham. Zurex intends to use the proceeds from its Series A financing to develop its products. In conjunction with the financing, new board members from its lead investor will join to support development efforts. No operating metrics or additional financial details were disclosed in the article.

Total raised

$12M

Funding rounds

4

Latest round

Series C

Latest activity

Aug 2016